Clinical trials: Moxifloxacin, open to volunteers
Community-acquired Pneumonia
Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)
The primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early…
- Trial name
- REACT (NCT06294600)
- Testing
- Clarithromycin 500mg, Tablets
- Where
- 24 sites in Greece
- Volunteers
- 330 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or…
- Trial name
- QUANTUM-TB (NCT07209761)
- Testing
- Bedaquiline, Quabodepistat, Pretomanid
- Where
- 42 sites in China, Georgia and 8 more
- Volunteers
- 532 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Endocarditis, Infective
Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.
Phase IV, open-label, randomized and multicenter clinical trial to prove that patients with Enterococcus faecalis infective endocarditis treated with an antibiotic treatment as a continuous infusion is non-inferior to the…
- Trial name
- DOBLEI (NCT06423898)
- Testing
- Ampicillin plus ceftriaxone in continuous infusion, Ampicillin plus ceftriaxone in intermittent infusion of 14 days, after which the treatment may be changed
- Where
- 18 sites in Spain
- Volunteers
- 284 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Brucellosis, Osteoarticular Brucellosis
All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis
Brucellosis is a globally distributed zoonosis with persistent clinical management challenges. The World Health Organization (WHO)-recommended doxycycline-rifampin (DOX-RIF) dual regimen may drive rifampin-associated…
- Trial name
- BRUCE-O (NCT07887152)
- Testing
- Doxycycline + Rifampicin + Ceftriaxone (intravenous therapy for 4 weeks), Triple oral regimen (Doxycycline + Rifampicin + Levofloxacin), Triple oral regimen (Doxycycline + Rifampicin + Moxifloxacin)
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital of Shihezi University
Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM)
A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis
The treatment of rifampicin-resistant/multidrug-resistant pulmonary tuberculosis (RR-TB) is characterized by a long treatment course, a high incidence of adverse reactions, a low cure rate, and a high recurrence rate.
- Conditions
- Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM), Pretomanid
- Trial name
- NCT07191834
- Volunteers
- 60 people
- Sponsor
- Wuhan Pulmonary Hospital
Infections Joint Prosthetic
Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections
Cutibacterium acnes is involved in nearly 40% of shoulder prosthetic joint infections (PJI). After shoulder prothesis, C. acnes mainly affects hip prosthesis.
- Trial name
- RIFACute (NCT05902221)
- Testing
- amoxicillin or moxifloxacin, amoxicillin or moxifloxacin + rifampicin
- Where
- 13 sites in France
- Volunteers
- 235 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Pulmonary Disease Due to Mycobacteria (Diagnosis)
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Mycobacterium abscessus (MABS) is a group of rapid-growing, multi-drug resistant non-tuberculous mycobacteria (NTM) causing infections in humans.
- Trial name
- FORMaT (NCT04310930)
- Testing
- Amikacin, Tigecycline, Imipenem
- Where
- 50 sites in Australia, Denmark and 5 more
- Volunteers
- 300 people
- Sponsor
- The University of Queensland
Tuberculosis
Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis
This study is based on the hypothesis that the pharmacokinetics of anti-tuberculosis drugs in TB children are different from adults.
- Trial name
- NCT03625739
- Testing
- anti-tuberculosis drug
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Beijing Children's Hospital
Community-acquired Pneumonia, Influenza, COVID-19
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients…
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Gram-negative Bacteremia
A Platform Trial for Gram Negative Bloodstream Infections
BALANCE+ is a perpetual multiple domain randomized controlled platform trial to evaluate various treatment strategies for Gram-negative bloodstream infections (GN BSIs).
- Trial name
- BALANCE+ (NCT06537609)
- Testing
- De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement
- Where
- 39 sites in Australia, Canada and 3 more
- Volunteers
- 2,500 people
- Sponsor
- Sunnybrook Health Sciences Centre
Corneal Abrasions
IN PATIENTS WITH CORNEAL ABRASIONS TREATED WITH COLLAGEN CORNEAL SHIELDS IN THE EMERGENCY DEPARTMENT SETTING
This is a single-center, double-arm, patient masked, randomized controlled trial. Subjects will be enrolled in the Emergency Department at the Penn State Milton S. Hershey Medical Center.
- Trial name
- NCT07225699
- Testing
- Oasis 72-Hour collagen shield
- Volunteers
- 60 people
- Sponsor
- Milton S. Hershey Medical Center
Keratitis Bacterial, Corneal Ulcer (Diagnosis)
Fluorometholone Study
The investigators seek to determine whether adjunctive topical fluorometholone (FML) improves best-corrected visual acuity (BCVA) at 3 months in patients with bacterial corneal ulcers compared with standard topical antibiotic…
- Trial name
- NCT07308938
- Testing
- Adjunctive Topical Fluorometholone (FML) 0.1%, Standard Topical Antibiotic Therapy
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Vishal Jhanji
Healthy
A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart
The main objective of this trial is to evaluate the effects of verducatib in the range of therapeutic to supra-therapeutic exposures on the QT/QTc-interval and other ECG parameters
- Trial name
- NCT07760246
- Testing
- Verducatib, Moxifloxacin
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Endophthalmitis
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
- Trial name
- NCT03244072
- Testing
- Moxifloxacin
- Where
- United States
- Volunteers
- 60,000 people, healthy volunteers welcome
- Sponsor
- Jason Ahee, M.D.
Tuberculosis, Tuberculosis Infection, Latent
Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in Kazakhstan
RIFA-REAL is a prospective observational longitudinal study evaluating the safety, feasibility, and effectiveness of rifapentine-based shorter treatment regimens for drug-susceptible tuberculosis (DS-TB) and tuberculosis…
- Conditions
- Tuberculosis, Tuberculosis Infection, Latent, Tuberculosis, Pulmonary, Drug Sensitive
- Trial name
- RIFA-REAL (NCT07668479)
- Volunteers
- 350 people
- Sponsor
- Public Union "Kazakhstan Association of Phthisiopulmonologists"
Uncomplicated Acute Appendicitis
Oral Antibiotic Outpatient Therapy vs. Placebo in the Treatment of Uncomplicated Acute Appendicitis
APPAC IV, a randomized double-blind multicenter clinical trial comparing once daily oral moxifloxacin with placebo in an outpatient setting aims to evaluate whether antibiotics and hospitalization or both can be omitted in the…
- Trial name
- APPAC IV (NCT06210269)
- Testing
- Moxifloxacin 400mg
- Where
- 9 sites in Finland
- Volunteers
- 498 people
- Sponsor
- Turku University Hospital
Helicobacter Infection
The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection
To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.
- Trial name
- NCT02373280
- Testing
- 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole), 7 day tailored PPI triple therapy (clarithromycin-containing triple therapy), 7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Healthy Volunteers, Safety After Oral Intake
Effects of Energy Drinks on Cardiovascular Endpoints
This is a clinical trial looking at the impact of energy drinks on heart related parameters. The study will enroll 3 participants who will be exposed to 8 different interventions.
- Trial name
- NCT07212803
- Testing
- Energy Drink B
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of the Pacific
Acute Myeloid Leukemia With FLT3/ITD Mutation
A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
This study plans to enroll 45 (Groups A, B, and C) to 75 healthy participants (including the sample size of other potential dose groups). The participants will be divided into three dose groups: 37.5 mg, 75 mg, and 150 mg.
- Trial name
- XY0206-CQT (NCT07162116)
- Testing
- XY0206, Moxifloxacin (400 mg)
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
PanACEA - STEP2C -01
This is a phase 2B/C, open label platform study that will compare the efficacy, safety of experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis.
- Trial name
- NCT05807399
- Testing
- BTZ-043, Rifampicin, Isoniazid
- Where
- 10 sites in Gabon, Malawi and 4 more
- Volunteers
- 390 people
- Sponsor
- Michael Hoelscher